−12.785 BRL
4.89 B BRL
20.07 B BRL
237.11 M
About BioNTech SE
Sector
Industry
CEO
Ugur Sahin
Website
Headquarters
Mainz
Founded
2008
ISIN
BRB1NTBDR005
FIGI
BBG00XX9JN55
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where B1NT34 is featured.
